JP2009539348A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539348A5 JP2009539348A5 JP2009513297A JP2009513297A JP2009539348A5 JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5 JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009513297 A JP2009513297 A JP 2009513297A JP 2009539348 A5 JP2009539348 A5 JP 2009539348A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 102000057308 human HGF Human genes 0.000 claims description 4
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 3
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims description 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims description 3
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims description 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims description 3
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims description 3
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 3
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 3
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81071406P | 2006-06-02 | 2006-06-02 | |
| US86046106P | 2006-11-21 | 2006-11-21 | |
| PCT/US2007/012950 WO2007143098A2 (en) | 2006-06-02 | 2007-06-01 | Hepatocyte growth factor (hgf) binding proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010167648A Division JP5528246B2 (ja) | 2006-06-02 | 2010-07-26 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539348A JP2009539348A (ja) | 2009-11-19 |
| JP2009539348A5 true JP2009539348A5 (OSRAM) | 2010-08-05 |
| JP4560582B2 JP4560582B2 (ja) | 2010-10-13 |
Family
ID=38802082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513297A Expired - Fee Related JP4560582B2 (ja) | 2006-06-02 | 2007-06-01 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
| JP2010167648A Expired - Fee Related JP5528246B2 (ja) | 2006-06-02 | 2010-07-26 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010167648A Expired - Fee Related JP5528246B2 (ja) | 2006-06-02 | 2010-07-26 | 肝細胞成長因子（ｈｇｆ）結合蛋白質 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US7659378B2 (OSRAM) |
| EP (2) | EP2380908A1 (OSRAM) |
| JP (2) | JP4560582B2 (OSRAM) |
| KR (1) | KR101196184B1 (OSRAM) |
| AR (1) | AR061170A1 (OSRAM) |
| AT (1) | ATE533787T1 (OSRAM) |
| AU (1) | AU2007254853B2 (OSRAM) |
| BR (1) | BRPI0712223A2 (OSRAM) |
| CA (1) | CA2654019A1 (OSRAM) |
| ES (1) | ES2378097T3 (OSRAM) |
| IL (2) | IL195038A0 (OSRAM) |
| MX (1) | MX2008015138A (OSRAM) |
| NO (1) | NO20085422L (OSRAM) |
| NZ (1) | NZ573819A (OSRAM) |
| WO (1) | WO2007143098A2 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0712222B1 (pt) * | 2006-06-02 | 2021-10-13 | Aveo Pharmaceuticals, Inc. | Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina |
| NZ573819A (en) * | 2006-06-02 | 2011-09-30 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
| SI2173379T1 (sl) | 2007-07-02 | 2015-12-31 | Oncomed Pharmaceuticals, Inc. | Sestavki in postopki za zdravljenje in diagnosticiranje raka |
| US20090123946A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US8846036B2 (en) * | 2007-10-19 | 2014-09-30 | Abbott Laboratories | Antibodies that bind to mammalian NGAL and uses thereof |
| US20090124022A1 (en) * | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Antibodies that bind to mammalian ngal and uses thereof |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| EP2899209A1 (en) * | 2008-04-29 | 2015-07-29 | Abbvie Inc. | Dual Variable Domain Immunoglobulins and uses thereof |
| CA2725873C (en) | 2008-05-29 | 2018-05-01 | Galaxy Biotech, Llc | Monoclonal antibodies to basic fibroblast growth factor |
| BRPI0913406A2 (pt) * | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
| EP2297208A4 (en) * | 2008-06-03 | 2012-07-11 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| EP2313435A4 (en) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| MX2011000117A (es) * | 2008-07-10 | 2011-02-25 | Toray Industries | Composicion farmaceutica para tratamiento y prevencion de cancer. |
| PL2842573T3 (pl) | 2008-11-07 | 2018-04-30 | Galaxy Biotech, Llc | Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów |
| SG2014006860A (en) * | 2008-11-12 | 2014-05-29 | Merck Sharp & Dohme | ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION |
| WO2010119991A2 (en) | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
| TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| RU2012112550A (ru) * | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
| US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| WO2012069557A1 (en) * | 2010-11-24 | 2012-05-31 | Glaxo Group Limited | Multispecific antigen binding proteins targeting hgf |
| MX349198B (es) | 2011-07-15 | 2017-07-18 | Oncomed Pharmaceuticals Inc * | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. |
| WO2013078223A1 (en) * | 2011-11-23 | 2013-05-30 | Children's Hospital & Research Center Oakland | Anti-factor h binding protein antibodies and methods of use thereof |
| TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2014012007A2 (en) | 2012-07-13 | 2014-01-16 | Oncomed Pharmaceuticals, Inc. | Rspo3 binding agents and uses thereof |
| UY35110A (es) | 2012-11-01 | 2014-05-30 | Abbvie Inc | Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas |
| US9481725B2 (en) | 2013-03-14 | 2016-11-01 | Alderbio Holdings, Llc | Antibodies to HGF and compositions containing |
| TW201444868A (zh) * | 2013-03-14 | 2014-12-01 | Alder Biopharmaceuticals Inc | Ｈｇｆ抗體及其組成物 |
| CA2904448A1 (en) | 2013-03-15 | 2014-09-18 | Tariq Ghayur | Dual specific binding proteins directed against il-1.beta. and/or il-17 |
| WO2015031578A1 (en) * | 2013-08-28 | 2015-03-05 | Abbvie Inc. | Hgf assay |
| CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
| MA40363A (fr) * | 2014-08-15 | 2017-06-21 | Oncomed Pharm Inc | Agents de liaison de rspo1 et leurs utilisations |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| US10550187B2 (en) | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| CA2959821C (en) | 2014-10-24 | 2024-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
| AU2017245099B2 (en) * | 2016-03-28 | 2021-07-29 | The Regents Of The University Of California | Anti-Ryk antibodies and methods of using the same |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| US11149094B2 (en) | 2017-06-05 | 2021-10-19 | Janssen Biotech, Inc. | Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations |
| CN111093693B (zh) * | 2017-06-15 | 2024-08-09 | 纪念斯隆-凯特林癌症中心 | 抗l1-cam抗体及其用途 |
| WO2019113393A1 (en) | 2017-12-06 | 2019-06-13 | Avidity Biosciences Llc | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| US11155638B2 (en) | 2018-05-08 | 2021-10-26 | Rhode Island Hospital | Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications |
| WO2020191293A1 (en) * | 2019-03-20 | 2020-09-24 | Javelin Oncology, Inc. | Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising |
| AU2020327537A1 (en) | 2019-08-12 | 2022-03-03 | Interna Technologies B.V. | New treatments involving miRNA-193a |
| EP4110917A1 (en) | 2020-02-28 | 2023-01-04 | InteRNA Technologies B.V. | Mirna-193a for promoting immunogenic cell death |
| WO2021195469A1 (en) * | 2020-03-27 | 2021-09-30 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5837676A (en) | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
| US6498144B1 (en) | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| WO2001034650A1 (en) | 1999-11-09 | 2001-05-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services | Hgf-sf monoclonal antibody combinations |
| JP2005538706A (ja) | 2001-07-12 | 2005-12-22 | ジェファーソン フーテ， | スーパーヒト化抗体 |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| AR042955A1 (es) | 2003-07-18 | 2005-07-13 | Amgen Inc | Agentes de union especifica al factor de crecimiento de hepatocitos |
| KR100556660B1 (ko) | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| MX2007015056A (es) | 2005-06-02 | 2008-03-11 | Galaxy Biotech Llc | Metodos para el tratamiento de tumores de cerebro con anticuerpos. |
| AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| BRPI0712222B1 (pt) * | 2006-06-02 | 2021-10-13 | Aveo Pharmaceuticals, Inc. | Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina |
| NZ573819A (en) * | 2006-06-02 | 2011-09-30 | Aveo Pharmaceuticals Inc | Hepatocyte growth factor (hgf) binding proteins |
| KR100829972B1 (ko) | 2006-07-14 | 2008-05-16 | 재단법인서울대학교산학협력재단 | 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법 |
-
2007
- 2007-06-01 NZ NZ573819A patent/NZ573819A/en not_active IP Right Cessation
- 2007-06-01 MX MX2008015138A patent/MX2008015138A/es active IP Right Grant
- 2007-06-01 AT AT07795607T patent/ATE533787T1/de active
- 2007-06-01 EP EP11159440A patent/EP2380908A1/en not_active Withdrawn
- 2007-06-01 ES ES07795607T patent/ES2378097T3/es active Active
- 2007-06-01 KR KR1020087032082A patent/KR101196184B1/ko not_active Expired - Fee Related
- 2007-06-01 CA CA002654019A patent/CA2654019A1/en not_active Abandoned
- 2007-06-01 AR ARP070102388A patent/AR061170A1/es not_active Application Discontinuation
- 2007-06-01 EP EP07795607A patent/EP2029627B1/en not_active Not-in-force
- 2007-06-01 WO PCT/US2007/012950 patent/WO2007143098A2/en not_active Ceased
- 2007-06-01 AU AU2007254853A patent/AU2007254853B2/en not_active Ceased
- 2007-06-01 US US11/757,094 patent/US7659378B2/en active Active
- 2007-06-01 JP JP2009513297A patent/JP4560582B2/ja not_active Expired - Fee Related
- 2007-06-01 BR BRPI0712223-3A patent/BRPI0712223A2/pt not_active IP Right Cessation
-
2008
- 2008-11-02 IL IL195038A patent/IL195038A0/en unknown
- 2008-12-30 NO NO20085422A patent/NO20085422L/no not_active Application Discontinuation
-
2009
- 2009-12-07 US US12/632,758 patent/US7935502B2/en not_active Expired - Fee Related
-
2010
- 2010-07-26 JP JP2010167648A patent/JP5528246B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-18 US US13/051,474 patent/US8268315B2/en not_active Expired - Fee Related
-
2012
- 2012-05-08 IL IL219655A patent/IL219655A0/en unknown
- 2012-08-20 US US13/589,652 patent/US8575318B2/en not_active Expired - Fee Related
-
2013
- 2013-09-27 US US14/039,912 patent/US20140178934A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539348A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2010246565A5 (OSRAM) | ||
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
| WO2006071441A3 (en) | Antibodies directed to gpnmb and uses thereof | |
| RU2531523C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2010526028A5 (OSRAM) | ||
| NZ585622A (en) | Hepatitis c virus antibodies | |
| WO2005016111A3 (en) | Antibodies directed to parathyroid hormone (PTH) and uses thereof | |
| JP2017114866A5 (OSRAM) | ||
| JP2010511388A5 (OSRAM) | ||
| JP2023093753A5 (OSRAM) | ||
| WO2006130458A3 (en) | Antibodies directed to cd20 and uses thereof | |
| JP2010535205A5 (OSRAM) | ||
| WO2006113643A3 (en) | High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies | |
| JP2018504105A5 (OSRAM) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| WO2005069970A3 (en) | Antibody specificity transfer using minimal essential binding determinants | |
| JP2013506428A5 (OSRAM) | ||
| WO2007070432A3 (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
| NZ601342A (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
| RU2015151505A (ru) | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) | |
| JP2020058359A5 (OSRAM) |